Literature DB >> 9127510

Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales.

M Ramsay1, E Kaczmarski, M Rush, R Mallard, P Farrington, J White.   

Abstract

We have reviewed data on meningococcal disease routinely collected in England and Wales from 1989 to 1995 to illustrate and explain changing patterns and guide future surveillance. Statutory notifications of meningococcal meningitis and septicaemia, laboratory confirmed infections, and death registrations coded as meningococcal disease were analysed in terms of their numbers, the age of cases, season of the report, and (if available) site of isolation, serogroup, and serotype. Case fatality rates were estimated for clinically diagnosed and culture confirmed cases. The number of cases notified each year, in particular those notified as septicaemia, rose significantly over the period (p < 0.0001) but there was no net change in the number of culture confirmed cases. Case fatality rates estimated from routine data fell, most markedly for cases notified as septicaemia, but the true case fatality rate of culture confirmed cases did not change between 1993 and 1995. These data suggest that reporting practice changed between 1989 and 1995 and that the ascertainment of clinically diagnosed disease improved, particularly for meningococcal septicaemia. Late in 1995, reports from all data sources increased and the age distribution of both notified and laboratory confirmed cases changed. These changes were accompanied by an increase in the proportion of infections due to Neisseria meningitidis of serogroup C and a significant increase in serotype C2a infections (p < 0.0001). Continuing efforts to reconcile data from several sources will be needed to ensure that routine data can be interpreted accurately to provide evidence for the development of future vaccination policy and to monitor vaccination programmes. In addition, the role of non-culture diagnosis will be crucial in enhancing surveillance based on clinical diagnoses.

Entities:  

Mesh:

Year:  1997        PMID: 9127510

Source DB:  PubMed          Journal:  Commun Dis Rep CDR Rev        ISSN: 1350-9349


  28 in total

1.  Changing epidemiology of bacterial meningitis among adults in England and Wales 1991-2002.

Authors:  A B Gjini; J M Stuart; D A Lawlor; K A V Cartwright; H Christensen; M Ramsay; R S Heyderman
Journal:  Epidemiol Infect       Date:  2006-06       Impact factor: 2.451

2.  Analysis of pathogen-host cell interactions in purpura fulminans: expression of capsule, type IV pili, and PorA by Neisseria meningitidis in vivo.

Authors:  O B Harrison; B D Robertson; S N Faust; M A Jepson; R D Goldin; M Levin; R S Heyderman
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

3.  Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci.

Authors:  Yanwen Li; Yao-hui Sun; Cathy Ison; Myron M Levine; Christoph M Tang
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Neisseria meningitidis lactate permease is required for nasopharyngeal colonization.

Authors:  Rachel M Exley; Linda Goodwin; Eva Mowe; Jonathan Shaw; Harry Smith; Robert C Read; Christoph M Tang
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Specificity of the immune response to a modified group B meningococcal polysaccharide conjugate vaccine.

Authors:  Samuel Moore; Esmé K Farley; Peter C Fusco; Francis Michon
Journal:  Clin Vaccine Immunol       Date:  2006-11-01

6.  Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines.

Authors:  Mathew A Diggle; Stuart C Clarke
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

7.  Differences in surface expression of NspA among Neisseria meningitidis group B strains.

Authors:  G R Moe; S Tan; D M Granoff
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 8.  Meningococcal vaccines: current issues and future strategies.

Authors:  Amanda C Cohn; Lee H Harrison
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

9.  Investigating the aetiology of and evaluating the impact of the Men C vaccination programme on probable meningococcal disease in England and Wales.

Authors:  J Granerod; K L Davison; M E Ramsay; N S Crowcroft
Journal:  Epidemiol Infect       Date:  2006-02-22       Impact factor: 2.451

10.  Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000.

Authors:  Jean-François Aguilera; Anne Perrocheau; Christine Meffre; Susan Hahné
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.